Shares of the telehealth company Hims & Hers Health Inc. (HIMS) soared 5.07% in Wednesday's intraday trading session.
The stock surge is likely driven by the buzz and attention surrounding Hims & Hers' provocative Super Bowl commercial that criticized weight-loss drug makers and the U.S. healthcare system. While prompting backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, the controversial ad has generated significant publicity for the company.
Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating according to IBD Stock Checkup. The company is set to report its earnings on February 24th, which could provide further insight into its performance and outlook.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。